Ambrosia Biosciences Series B

Date: 31-Mar-2026 | Size: US$100M | Therapeutic area: Cardiometabolic / obesity

Investors: Co-led by Blue Owl Healthcare Opportunities, Redmile, and Deep Track Capital; participation from BVF Partners, Boulder Ventures, Janus Henderson Investors, Samsara BioCapital, and an undisclosed institutional investor

What they do: Biotech developing oral small-molecule cardiometabolic therapies, led by an oral GLP-1 receptor agonist the company says has best-in-class potential. Proceeds will support advancement of the lead oral obesity program and other cardiometabolic assets into clinical development.

Source

Oncomatryx Series B

Date: 30-Mar-2026 | Size: US$67M | Therapeutic area: Oncology / tumour-microenvironment ADCs

Investors: Spanish government-backed and regional investors including CDTI, Kutxa Fundazioa, the Basque Government, Ekarpen VC, BBK, and others

What they do: Spanish biotech developing ADCs that target the tumour microenvironment, with a focus on cancer-associated fibroblasts. Proceeds will support clinical development of lead candidate OMTX705 and help advance OMTX105 and additional Quantum ADC programs into clinical trials.

Source

Pinnacle Medicines Series B

Date: 26-Mar-2026 | Size: US$89M | Therapeutic area: Oral peptide therapeutics (immunology + cardiometabolic)

Investors: Co-led by Lilly Asia Ventures (LAV) and Foresite Capital; participation from Quan Capital, Hankang Capital, RA Capital Management, Logos Capital, and existing investors including OrbiMed

What they do: Biotech developing a new generation of oral peptide medicines designed to combine biologic-level efficacy with the convenience of oral dosing. Proceeds will support lead programs through clinical proof of concept, initially focused on immunology and cardiometabolic diseases, and expand its AI- and physics-based peptide discovery platform.

Source